Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Douglas C. A. Taylor, MBA
Articles
Economic Model of Granulocyte Colony-Stimulating Factors for Patients Receiving Chemotherapy
Douglas C. A. Taylor, MBA;Kelly Fust, MS;Michelle E. Skornicki, MPH;Gregory Hill, BA;Richard L. Barron, MS;Milton C. Weinstein, PhD
December 11th 2012For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Read More
Latest Updated Articles
Published: June 12th 2025 | Updated: June 16th 2025
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 10th 2025 | Updated: June 12th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 2nd 2025 | Updated: June 11th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 3rd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: May 30th 2025 | Updated: June 5th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: April 18th 2025 | Updated: April 21st 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
